VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 362 filers reported holding VANECK VECTORS ETF TR in Q4 2016. The put-call ratio across all filers is 0.93 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,873,676 | -3.2% | 2,708,052 | +8.3% | 24.11% | +21.3% |
Q2 2023 | $75,294,236 | -2.4% | 2,500,639 | +4.8% | 19.88% | -23.7% |
Q1 2023 | $77,184,378 | +20.8% | 2,385,916 | +7.0% | 26.05% | -1.4% |
Q4 2022 | $63,878,311 | -6.5% | 2,228,832 | -21.3% | 26.42% | -23.8% |
Q3 2022 | $68,310,000 | -6.3% | 2,832,115 | +6.3% | 34.65% | -3.6% |
Q2 2022 | $72,913,000 | -26.6% | 2,663,041 | +2.8% | 35.94% | +2.2% |
Q1 2022 | $99,338,000 | -16.3% | 2,590,335 | -30.1% | 35.16% | -13.8% |
Q4 2021 | $118,664,000 | +69.3% | 3,704,791 | +55.8% | 40.77% | +41.5% |
Q3 2021 | $70,075,000 | -9.1% | 2,377,855 | +4.8% | 28.82% | +10.9% |
Q2 2021 | $77,080,000 | +9.3% | 2,268,412 | +4.6% | 25.99% | -3.8% |
Q1 2021 | $70,498,000 | -9.3% | 2,169,200 | +0.5% | 27.01% | -3.5% |
Q4 2020 | $77,759,000 | +122.6% | 2,158,789 | +63.3% | 27.99% | -26.7% |
Q3 2016 | $34,934,000 | +24.6% | 1,321,823 | +30.7% | 38.20% | +18.4% |
Q2 2016 | $28,030,000 | – | 1,011,600 | – | 32.26% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |